Cargando…
Chemokines in Gestational Diabetes Mellitus
BACKGROUND: Studies investigating chemokines in gestational diabetes mellitus (GDM) have yielded mixed results. The purpose of this meta-analysis was to explore whether concentrations of chemokines in patients with GDM differed from that of the controls. METHODS: Following Preferred Reporting Items...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860907/ https://www.ncbi.nlm.nih.gov/pubmed/35211112 http://dx.doi.org/10.3389/fimmu.2022.705852 |
_version_ | 1784654767541190656 |
---|---|
author | Liu, Hongying Liu, Aizhong Kaminga, Atipatsa C. McDonald, Judy Wen, Shi Wu Pan, Xiongfeng |
author_facet | Liu, Hongying Liu, Aizhong Kaminga, Atipatsa C. McDonald, Judy Wen, Shi Wu Pan, Xiongfeng |
author_sort | Liu, Hongying |
collection | PubMed |
description | BACKGROUND: Studies investigating chemokines in gestational diabetes mellitus (GDM) have yielded mixed results. The purpose of this meta-analysis was to explore whether concentrations of chemokines in patients with GDM differed from that of the controls. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Web of Science, Embase, Cochrane Library, and PubMed databases for articles, published in any language, on chemokines and GDM through August 1st, 2021. The difference in concentrations of chemokines between patients with GDM and controls was determined by a standardized mean difference (SMD) with a 95% confidence interval (CI), calculated in the meta-analysis of the eligible studies using a random-effects model with restricted maximum-likelihood estimator. RESULTS: Seventeen studies met the inclusion criteria for the meta-analysis. Altogether, they included nine different chemokines comparisons involving 5,158 participants (1,934 GDM patients and 3,224 controls). Results showed a significant increase of these chemokines (CCL2, CXCL1, CXCL8, CXCL9, and CXCL12) in the GDM patients compared with the controls. However, there was a significant decrease of the chemokines, CCL4, CCL11 and CXCL10, in the GDM patients compared with the controls. Moreover, subgroup analysis revealed a potential role of chemokines as biomarkers in relation to laboratory detection (different sample type and assay methods) and clinical characteristics of GDM patients (ethnicity and body mass index). CONCLUSION: GDM is associated with several chemokines (CCL2, CCL4, CCL11, CXCL1, CXCL8, CXCL9, CXCL10 and CXCL12). Therefore, consideration of these chemokines as potential targets or biomarkers in the pathophysiology of GDM development is necessary. Notably, the information of subgroup analysis underscores the importance of exploring putative mechanisms underlying this association, in order to develop new individualized clinical and therapeutic strategies. |
format | Online Article Text |
id | pubmed-8860907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88609072022-02-23 Chemokines in Gestational Diabetes Mellitus Liu, Hongying Liu, Aizhong Kaminga, Atipatsa C. McDonald, Judy Wen, Shi Wu Pan, Xiongfeng Front Immunol Immunology BACKGROUND: Studies investigating chemokines in gestational diabetes mellitus (GDM) have yielded mixed results. The purpose of this meta-analysis was to explore whether concentrations of chemokines in patients with GDM differed from that of the controls. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Web of Science, Embase, Cochrane Library, and PubMed databases for articles, published in any language, on chemokines and GDM through August 1st, 2021. The difference in concentrations of chemokines between patients with GDM and controls was determined by a standardized mean difference (SMD) with a 95% confidence interval (CI), calculated in the meta-analysis of the eligible studies using a random-effects model with restricted maximum-likelihood estimator. RESULTS: Seventeen studies met the inclusion criteria for the meta-analysis. Altogether, they included nine different chemokines comparisons involving 5,158 participants (1,934 GDM patients and 3,224 controls). Results showed a significant increase of these chemokines (CCL2, CXCL1, CXCL8, CXCL9, and CXCL12) in the GDM patients compared with the controls. However, there was a significant decrease of the chemokines, CCL4, CCL11 and CXCL10, in the GDM patients compared with the controls. Moreover, subgroup analysis revealed a potential role of chemokines as biomarkers in relation to laboratory detection (different sample type and assay methods) and clinical characteristics of GDM patients (ethnicity and body mass index). CONCLUSION: GDM is associated with several chemokines (CCL2, CCL4, CCL11, CXCL1, CXCL8, CXCL9, CXCL10 and CXCL12). Therefore, consideration of these chemokines as potential targets or biomarkers in the pathophysiology of GDM development is necessary. Notably, the information of subgroup analysis underscores the importance of exploring putative mechanisms underlying this association, in order to develop new individualized clinical and therapeutic strategies. Frontiers Media S.A. 2022-02-08 /pmc/articles/PMC8860907/ /pubmed/35211112 http://dx.doi.org/10.3389/fimmu.2022.705852 Text en Copyright © 2022 Liu, Liu, Kaminga, McDonald, Wen and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Liu, Hongying Liu, Aizhong Kaminga, Atipatsa C. McDonald, Judy Wen, Shi Wu Pan, Xiongfeng Chemokines in Gestational Diabetes Mellitus |
title | Chemokines in Gestational Diabetes Mellitus |
title_full | Chemokines in Gestational Diabetes Mellitus |
title_fullStr | Chemokines in Gestational Diabetes Mellitus |
title_full_unstemmed | Chemokines in Gestational Diabetes Mellitus |
title_short | Chemokines in Gestational Diabetes Mellitus |
title_sort | chemokines in gestational diabetes mellitus |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860907/ https://www.ncbi.nlm.nih.gov/pubmed/35211112 http://dx.doi.org/10.3389/fimmu.2022.705852 |
work_keys_str_mv | AT liuhongying chemokinesingestationaldiabetesmellitus AT liuaizhong chemokinesingestationaldiabetesmellitus AT kamingaatipatsac chemokinesingestationaldiabetesmellitus AT mcdonaldjudy chemokinesingestationaldiabetesmellitus AT wenshiwu chemokinesingestationaldiabetesmellitus AT panxiongfeng chemokinesingestationaldiabetesmellitus |